Estimation of susceptibility hospital strains of Mycobacterium tuberculosis (Mtb) Beijing to disinfectants Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Infection of the respiratory mucosa by Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB) and Mycobacterium smegmatis (MS) Source: Eur Respir J 2001; 18: Suppl. 33, 308s Year: 2001
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001
In vitro activity of triclosan ( TCN ) and thiolactomycin ( TLM ) against multi-drug-resistant ( MDR ) strains of mycobacterium tuberculosis ( M. tb ) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Influence of glutoxim and its derivatives on the growth of mycobacterium tuberculosis (Mtb) Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
On the nature of Mycobacterium tuberculosis-latent bacilli Source: Eur Respir J 2004; 24: 1044-1051 Year: 2004
Circulation of multidrug resistant strains of Mycobacterium tuberculosis in Abkhasia Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006
Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb )Source: Eur Respir J 2005; 26: Suppl. 49, 700s Year: 2005
Deficient in silico selection of mycobacterium tuberculosis (MTB) epitopes in tuberculosis (TB) patients Source: Eur Respir J 2006; 28: Suppl. 50, 801s Year: 2006
Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Express-diagnosing of multidrug resistant bacterial and L-forms of mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008
In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q) Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003